Figure 4From: Inhibition of neutrophil elastase attenuates airway hyperresponsiveness and inflammation in a mouse model of secondary allergen challenge: neutrophil elastase inhibition attenuates allergic airway responsesTreatment with sivelestat reduces AHR and airway inflammation 48 hr after secondary challenge. (A) Changes in RL 48 hr after secondary challenge. Results for each group are expressed as the mean ± SD. (n = 16 in each group). (B) Cell composition in BAL fluid. Results for each group are expressed as the mean ± SD. (n = 16 in each group). (C) H&E–stained lung tissue (final magnification:x400). (a) PBS/OVA/vehicle/OVA, (b) OVA/OVA/vehicle/OVA, (c) OVA/OVA/Sivelestat/OVA. (D) Inflammatory cell numbers in the peribronchial and perivascular tissue (final magnification:x1000). (E) Anti-Gr-1 monoclonal antibody stained lung tissue (final magnification:x400). (a) PBS/OVA/vehicle/OVA, (b) OVA/OVA/vehicle/OVA, (c) OVA/OVA/Sivelestat/OVA. (F) PAS staining (final magnification:x1000). (a) PBS/OVA/vehicle/OVA, (b) OVA/OVA/vehicle/OVA, (c) OVA/OVA/Sivelestat/OVA. (G) The number of mucus-positive cells. Data represent the mean ± SD. (n = 8 in each group). *Significant differences (P<0.05) between PBS/OVA/vehicle/OVA and OVA/OVA/vehicle/OVA. #Significant differences (P < 0.05) between OVA/OVA/vehicle/OVA and OVA/OVA/Sivelestat/OVA.Back to article page